REZOLUTE, INC.
RZLT US76200L3096
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-63% | -59% | -47% | 385% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Roberts Brian Kenneth CMO |
4.38 USD |
2,500 Bought |
10,939 USD |
25/06/2025 | 25/06/2025 |
Evans Daron CFO |
4.05 USD |
5,000 Bought |
20,250 USD |
24/06/2025 | 24/06/2025 |
Evans Daron CFO |
4.05 USD |
5,000 Bought |
20,250 USD |
24/06/2025 | 24/06/2025 |
Kreher Nerissa |
3.25 USD |
3,076 Bought |
9,997 USD |
13/06/2025 | 13/06/2025 |
Kim Young-jin |
3.25 USD |
1,230,769 Bought |
3,999,999 USD |
13/06/2025 | 13/06/2025 |
Kim Young-jin |
3.25 USD |
1,230,769 Bought |
3,999,999 USD |
13/06/2025 | 13/06/2025 |
Kreher Nerissa |
3.25 USD |
3,076 Bought |
9,997 USD |
13/06/2025 | 13/06/2025 |
Hogenhuis Wladimir |
2.92 USD |
6,758 Bought |
19,733 USD |
01/04/2025 | 31/03/2025 |
Elam Nevan C CEO |
2.85 USD |
12,302 Bought |
34,999 USD |
27/03/2025 | 27/03/2025 |
Evans Daron CFO |
2.89 USD |
10,000 Bought |
28,900 USD |
26/03/2025 | 26/03/2025 |